Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, announced that Danny Brannagan, its Chief Financial Officer, will be stepping down in January 2022 to pursue other endeavours. The Company intends to appoint an interim Chief Financial Officer while it undertakes a search for a new Chief Financial Officer with a proven track record of financial leadership and experience to help Covalon with its next phase of growth.
“I would like to thank Danny for his contributions to Covalon and we wish him the best in his future endeavors,” said Brian Pedlar, Chief Executive Officer of Covalon.
About Covalon
Covalon Technologies Ltd. is a researcher, developer, manufacturer, and marketer of patent-protected medical products that improve patient outcomes and save lives in the areas of advanced wound care, infection management and surgical procedures. cleverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTQX Market under the symbol CVALF.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release